| Product Code: ETC9959786 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The United States saw a notable increase in autoimmune and inflammatory immunomodulators import shipments in 2024, with top exporting countries including Switzerland, Ireland, Singapore, India, and Germany. The market showed a shift from moderate to low concentration, indicating a more diverse import landscape. The compound annual growth rate (CAGR) from 2020 to 2024 stood at 2.85%, with a particularly strong growth rate of 7.62% from 2023 to 2024. This data suggests a growing demand for these products in the US market, driven by imports from a variety of key countries.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Autoimmune and Inflammatory Immunomodulators Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Autoimmune and Inflammatory Immunomodulators Market - Industry Life Cycle |
3.4 United States (US) Autoimmune and Inflammatory Immunomodulators Market - Porter's Five Forces |
3.5 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 United States (US) Autoimmune and Inflammatory Immunomodulators Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases in the US |
4.2.2 Growing awareness about immunomodulatory therapies |
4.2.3 Technological advancements in drug development for autoimmune and inflammatory conditions |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approvals |
4.3.2 High cost associated with immunomodulatory treatments |
4.3.3 Potential side effects and safety concerns of immunomodulators |
5 United States (US) Autoimmune and Inflammatory Immunomodulators Market Trends |
6 United States (US) Autoimmune and Inflammatory Immunomodulators Market, By Types |
6.1 United States (US) Autoimmune and Inflammatory Immunomodulators Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Biologics, 2021- 2031F |
6.1.4 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Small Molecules, 2021- 2031F |
6.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Oncology, 2021- 2031F |
6.2.3 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Respiratory, 2021- 2031F |
6.2.4 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By HIV, 2021- 2031F |
6.2.5 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Rheumatoid Arthritis, 2021- 2031F |
6.2.6 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Autoimmune and Inflammatory Immunomodulators Market Import-Export Trade Statistics |
7.1 United States (US) Autoimmune and Inflammatory Immunomodulators Market Export to Major Countries |
7.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market Imports from Major Countries |
8 United States (US) Autoimmune and Inflammatory Immunomodulators Market Key Performance Indicators |
8.1 Patient adherence rates to immunomodulatory therapies |
8.2 Number of clinical trials evaluating new immunomodulators |
8.3 Rate of adoption of novel treatment approaches in autoimmune and inflammatory conditions |
9 United States (US) Autoimmune and Inflammatory Immunomodulators Market - Opportunity Assessment |
9.1 United States (US) Autoimmune and Inflammatory Immunomodulators Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market Opportunity Assessment, By Application, 2021 & 2031F |
10 United States (US) Autoimmune and Inflammatory Immunomodulators Market - Competitive Landscape |
10.1 United States (US) Autoimmune and Inflammatory Immunomodulators Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Autoimmune and Inflammatory Immunomodulators Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |